Literature DB >> 34137072

Immune-Related Hematologic Adverse Events in the Context of Immune Checkpoint Inhibitor Therapy.

Antoine N Saliba1,2, Zhuoer Xie1,2, Alexandra S Higgins1,2, Xavier A Andrade-Gonzalez1,2, Harry E Fuentes-Bayne1,2, Paul J Hampel1,2, Lionel A Kankeu Fonkoua1,2, Daniel S Childs1,2, Sagar Rakshit1,2, Evandro D Bezerra1,2, Anuhya Kommalapati1,2, Yanyan Lou3, Candido E Rivera3, Katharine A Price2, Ashish Chintakuntlawar2, Yiyi Yan2, Anna J Schwecke2, Matthew S Block2, Uma Thanarajasingam4, Gita Thanarajasingam1, Alexandra P Wolanskyj-Spinner1, Ariela L Marshall1,5, Lisa A Kottschade2, Ronald S Go1, Aref Al-Kali1.   

Abstract

Year:  2021        PMID: 34137072     DOI: 10.1002/ajh.26273

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  1 in total

1.  Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma.

Authors:  Andrew M Evens; Justin S Brandt; Cody J Peer; Tyler Yin; Dale Schaar; Faheem Farooq; Brett Mozarsky; William D Figg; Elad Sharon
Journal:  Am J Hematol       Date:  2022-03-21       Impact factor: 13.265

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.